As AURKA inhibitors have demonstrated anti-tumor activities either as a single agent or in combination in MYCN-positive human glioblastoma and AURKs are attractive therapeutic targets in c-Myc-driven lymphoproliferative disorders [32]. The gene discussed is AURKA; the disease is lymphoproliferative syndrome.